# An Extension Study to Determine the Efficacy and Safety of STI571 in Participants With Chronic Myeloid Leukemia Who Are Refractory to or Intolerant of Interferon-Alpha

> **NCT00171223** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 532 (actual)

## Conditions studied

- Leukemia, Myelogenous, Chronic, BCR-ABL Positive

## Interventions

- **DRUG:** STI571

## Key facts

- **NCT ID:** NCT00171223
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1999-12-06
- **Primary completion:** 2013-11-29
- **Final completion:** 2013-11-29
- **Target enrollment:** 532 (ACTUAL)
- **Last updated:** 2021-07-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00171223

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00171223, "An Extension Study to Determine the Efficacy and Safety of STI571 in Participants With Chronic Myeloid Leukemia Who Are Refractory to or Intolerant of Interferon-Alpha". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00171223. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*